Mindstate Design Labs

Mindstate Design Labs is pioneering a novel approach to mental health treatment through its clinical-stage AI neuroengineering platform. The company aims to create pharmaceuticals that can induce specific, therapeutically beneficial emotional states on demand. Their core technology, the Osmanthus platform, leverages advanced AI models to analyze extensive datasets of psychoactive pharmacology and phenomenology. This allows them to identify precise combinations of neurotransmitter receptor activities associated with various emotional, cognitive, and perceptual states.

Their lead program, MSD-001, is engineered for rapid action, promoting enhanced emotional and cognitive flexibility without causing hallucinations. Currently undergoing human trials, MSD-001 is intended to serve as a foundational ingredient for a range of drug combinations, effectively delivering "emotions in a bottle," such as empathy, awe, clarity, or beauty. Mindstate Design Labs envisions a future where emotional well-being can be precisely and effectively managed through targeted pharmaceutical interventions.